Targeting Launch of Platform by Year's End, GnuBio Bets on Gene Panels, Replacing Sanger Assays | GenomeWeb

By Julia Karow

GnuBio plans to release a beta version of its desktop microfluidic sequencer in the second quarter and to launch the system commercially by the end of the year, the company said earlier this month.

The firm plans to focus on gene panel resequencing and replacing Sanger-based single-gene assays with its instrument, which integrates target amplification, sequencing, and data analysis. GnuBio promises its customers low cost, high accuracy, and fast turnaround times.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.